Post

More from @anishmoonka

Anish Moonka

@anishmoonka

May 24

https://x.com/anishmoonka/status/2035892187561439706

A male bee mates for less than 5 seconds in midair. The ejaculation is so explosive you can hear it pop from a few feet away. His body rips in half. He falls dead before hitting the ground. And he is one of the lucky males in the hive.

When a male bee, called a drone, chases down a queen mid-flight at speeds of 22 miles per hour, his entire reproductive organ turns inside out. The pressure required for this comes from nearly all the blood in his body, which rushes downward to force the organ outward like a spring. The semen fires into the queen with so much force it makes the audible pop. The organ then snaps off and stays lodged inside her like a cork. As he flips backward off her body, his abdomen rips open. The next drone waiting his turn has to physically yank out the dead male's cork before he can mate. The same thing then happens to him.

The queen does this 12 to 20 times in a single afternoon. She flies up to a spot in the sky that beekeepers call a drone congregation area. Picture an invisible meeting point about 50 to 130 feet above the ground where up to 11,000 male bees from as many as 240 different hives are hovering, waiting for her. These spots stay in the exact same locations year after year, sometimes for over a decade. No one fully understands how brand new drones, born only weeks earlier, find them.

By the end of her mating run, the queen has collected around 100 million sperm cells. She keeps only 5 to 6 million in a tiny internal storage organ that keeps them alive for years. From that supply, she uses just two sperm cells per egg for the rest of her life, laying up to 2,000 eggs a day for 2 to 7 years. After that one afternoon in the sky, she will never mate again.

A 2019 study from UC Riverside, the University of Copenhagen, and the University of Western Australia found that bee semen contains toxic proteins that temporarily blind the queen by interfering with how vision genes function in her brain. If she can't see well, she can't fly out again to mate with more males. Their semen also carries a separate protein that attacks and kills sperm cells from rival drones still inside her. The males keep competing long after every one of them is dead.

The 99.9% of drones who never get to mate have it worse. As autumn arrives, the female worker bees in the hive stop feeding their brothers, then drag them out of the entrance after biting off their wings. The drones can't fly back in. They starve or freeze in the grass within days. The colony raises a fresh batch of disposable males the next spring, and the whole cycle starts over.

https://x.com/anishmoonka/status/2035892187561439706

Thanks for going down this rabbit hole ❤️

Follow @anishmoonka for daily stories across science, history, psychology, culture & AI.

—————

Sources:

Liberti et al. 2019 eLife study on seminal fluid compromising queen vision elifesciences.org/articles/45009

ScienceDaily coverage of UC Riverside queen-blinding findings sciencedaily.com/releases/2019/…

Wikipedia: Drone bee (endophallus biology, mating mechanics, haplodiploidy) en.wikipedia.org/wiki/Drone_(be…

Age-specific olfactory attraction paper (11,000 drones, 240 colonies, DCA dynamics) ncbi.nlm.nih.gov/pmc/articles/P…

Apiary Project: Drone biology, mating, and expulsion (5-second mating, audible pop, autumn eviction) apiaryproject.com/blog/drone-bee…

Part 2. When a baby queen bee chews her way out of her cell, the very first thing she does is hunt down her sleeping sisters and sting them to death, one by one, often before they have even hatched. She is less than a day old. This is how every queen in every honeybee hive on Earth begins her life.

The queen and every worker bee in her hive share the exact same DNA. They are genetic twins. The only thing that turns one fertilized egg into a queen and another into a worker is what the baby gets fed in its first few days of life. Larvae chosen for the throne are flooded with royal jelly, a milky substance secreted from glands in the heads of nurse bees. It contains a fatty acid (10-HDA) that flips chemical switches inside the larva's cells, turning on a different set of genes without changing the underlying DNA. This entire field of biology, where diet rewires which genes activate, exists partly because scientists were trying to figure out how honeybees pull this off.

A queen develops in just 16 days, faster than any other bee in the hive. She emerges with a smooth, curved stinger built specifically for killing other queens. Workers have barbed stingers that rip out and kill them after one sting. The queen's stinger is reusable. She walks the comb making a high-pitched piping sound that beekeepers can actually hear with their ear pressed to a hive. Her unhatched sisters, still trapped in their wax cells, pipe back. She uses the sound to find them, slices a hole in the side of each cell, and stings them through the wall.

Once she has killed everyone, she flies out once in her life to mate. Then she returns to the hive and never leaves it again for 2 to 5 years. She lays up to 2,000 eggs a day, more than her own body weight every 24 hours, sometimes over a million eggs total in her lifetime. The whole time, she leaks scent chemicals from glands in her face that drift through the hive on the bodies of workers grooming her. Those chemicals chemically castrate her daughters, shutting down their ovaries so they cannot lay eggs of their own. The worker bees around her live just 6 weeks in summer. She lives 20 to 40 times longer.

She is not actually in charge of anything. The workers run the colony. The moment her egg-laying drops or her scent chemicals weaken (which happens if she gets infected with a virus or simply ages), the workers vote her out. They start building emergency queen cells, raise replacements, then murder her. The execution method is called "balling." 15 to 50 worker bees pile on top of her in a tight ball and use their own body heat to cook her alive from the inside. In commercial American beehives, over half of queens get replaced within 6 months. The mother of the entire colony is disposable the second she stops producing.

The new queen then chews her way out, kills her sisters, mates once, and the cycle starts again. A honeybee colony is not really ruled by a queen at all. It is a 50,000-female democracy that grows its own monarchs the way humans grow vegetables, then composts them when they wilt.

Read 10 tweets

Anish Moonka

@anishmoonka

May 24

https://x.com/anishmoonka/status/2057858071133557160

Oxygen already killed most of the life on Earth once. The first time it filled the air, around 2.4 billion years ago, it was so poisonous that nearly everything alive died. Scientists call it the Oxygen Catastrophe.

Back then the oceans were full of tiny microbes, and none of them used oxygen. Then one kind, an ancestor of the green scum you still see on ponds, started giving off oxygen as a waste gas, the same way you breathe out air you don’t need. Oxygen is a wrecker. It rips apart the delicate machinery inside a living cell, including the DNA, and as it built up in the water and then the sky, it triggered the first mass extinction this planet had ever seen.

A few survivors hid in the mud and deep underground where the gas couldn’t reach, and some of their descendants are still down there. But one tiny cell did something nobody else did. It ate a bacterium that had learned to use oxygen rather than die from it, and instead of digesting its meal, it kept it alive inside itself. That trapped bacterium became the mitochondria, the little engines that power your cells right now. Almost every cell you are made of carries hundreds or thousands of them, all descended from that one strange truce with a poison.

The trade was worth it because burning food with oxygen releases about 18 times more energy than burning it without. It is the reason anything can swim fast or think hard. Every big, fast-moving animal on Earth, you included, runs on the gas that almost ended life.

Oxygen changed the sky too. Some of it floated up high and turned into ozone, a thin layer that blocks most of the sun’s harshest rays. Before that shield existed, raw sunlight was strong enough to fry the DNA of anything out in the open, so life had to stay underwater, where a few feet of sea soaked up the danger. For almost two billion years, nothing lived on land at all. Only once the ozone grew thick enough, a few hundred million years ago, did the first plants and animals crawl out of the water.

And the old poison never really left. Every second, the oxygen your cells burn throws off tiny broken bits called free radicals, and they keep nicking your DNA and the proteins around it. The damage adds up, slowly, your whole life. Back in 1956 a scientist named Denham Harman suggested this slow rusting from the inside is a big reason we get old. People still argue about how much it matters, and no antioxidant pill has ever been shown to make anyone live longer, but the basic idea has held up. The gas keeping you alive right now is also quietly wearing you down, year by year. The joke just got the timing wrong. Oxygen really does kill slowly, and billions of years before we showed up, it already proved it can kill fast.

https://x.com/anishmoonka/status/2057858071133557160

Thanks for going down this rabbit hole ❤️

Follow @anishmoonka for daily stories across science, history, psychology, culture & AI.

—————

Sources:

Great Oxidation Event, oxygen as poison to early anaerobic life — American Society for Microbiology
<asm.org/articles/2022/…>

Lynn Margulis and the endosymbiotic origin of mitochondria from an engulfed aerobic bacterium — PNAS
<pnas.org/doi/10.1073/pn…>

The Free Radical Theory of Aging Matures (Beckman & Ames, 1998), Harman 1956 origin — Physiological Reviews
<journals.physiology.org/doi/full/10.11…>

Theoretical ATP yield, oxygen vs no oxygen (about 2 vs 36 to 38) — Biology LibreTexts
<bio.libretexts.org/Bookshelves/Mi…>

Ozone shield formation and the delayed colonization of land — Earth Archives
<eartharchives.org/articles/life-…>

Part 2. Every time you hold your breath, the thing that finally forces you to gasp is carbon dioxide piling up in your blood, the same waste gas you breathe out. Your body watches that gas like a hawk. The oxygen you actually need to stay alive, it barely tracks at all, and that blind spot quietly kills strong swimmers every year.

The control sits in your brainstem, at the base of your skull, in a patch that runs your breathing without you ever thinking about it. It is constantly measuring carbon dioxide, and when the level creeps up even a little, it pushes you to breathe harder to clear the excess. A tiny rise in that one gas causes a big jump in how hard you breathe. Oxygen gets its own sensors, tucked into the big arteries in your neck, but they stay quiet until oxygen drops to dangerous levels, and even then their warning is faint next to the carbon dioxide alarm.

This is why holding your breath feels the way it does. That growing pressure in your chest near the end is the carbon dioxide alarm getting louder until you cannot hold out. Free divers train this exact feeling, learning to stay calm while the gas climbs, which is how some of them stay under for minutes on a single breath.

The blind spot turns deadly when people mute the alarm on purpose. Take a few fast, deep breaths before going underwater and you flush out so much carbon dioxide that the urge to breathe stays switched off far longer than it should. The trap is that clearing carbon dioxide does almost nothing for your oxygen. So a swimmer can glide along feeling fine while oxygen drains away, then black out with no warning. Water-safety groups call it shallow water blackout, and it is one of the quiet killers of fit, capable swimmers.

The same gap shows up far from any pool. Pilots who lose cabin pressure often feel no alarm as the oxygen thins, just a warm, slightly drunk calm while their judgment falls apart, which is why flight crews sit in low-oxygen chambers during training to learn what their own oxygen starvation feels like before it can fool them in the air. In sealed tanks and grain silos where the air has been pushed out by another gas, people can pass out after a few breaths without ever feeling short of air, because no carbon dioxide is building up to trip the alarm. Low oxygen can kill you, which is the exact fear in the joke. Your body just spends far more effort warning you about the gas you breathe out than the one you would die without.

Read 6 tweets

Anish Moonka

@anishmoonka

May 23

https://x.com/anishmoonka/status/2057854234536951872

Mark Cuban sold his company to Yahoo for $5.7 billion in 1999. Overnight, he was a billionaire. There was just one problem: Yahoo paid him in its own stock, he was banned from selling it for six months, and that stock was sitting on a bubble that was about to pop.

So he was a billionaire who couldn't actually reach his money. He owned 14.6 million shares of Yahoo, worth around $1.4 billion, and he couldn't turn a single one into cash. Even after the six months ran out, selling them was its own trap. Nobody buys 14.6 million shares at once. The second he started dumping that much stock, the price would slide before he finished, dragging his fortune down with it.

Here is what he did instead. He bought insurance on his own stock.

You can buy a contract that locks in a guaranteed price someone has to pay you for your shares later. Cuban locked his in at $85 each. From then on, no matter how far Yahoo fell, he could still sell at $85 and walk away with more than a billion dollars. The problem is that this kind of protection costs money, and insuring $1.4 billion is expensive.

He covered the cost in a strange way. He sold off his claim to Yahoo's biggest gains. He signed a second contract that said if the stock ever climbed past $205, someone else could buy his shares at that price and keep anything above it. He was betting it would never get there, and the money from that bet paid for his insurance almost exactly. The whole setup cost him nothing.

For a while, he looked like a fool. Yahoo kept climbing, blew past $205, and ran all the way to about $237. He had locked himself out of a fortune in gains, right at the top. Then the bubble burst. Yahoo went into freefall and crashed to roughly $13. Almost everyone holding it got wiped out. Cuban's $85 floor held the entire way down, and he walked off with his money still in his pocket.

The company that set all of this in motion never made it. Yahoo killed Broadcast .com in 2002, three years after paying $5.7 billion for it. Yahoo itself was sold off in 2017 for about $4.5 billion, less than it once paid for Cuban's company alone. Selling made him a billionaire on paper. The insurance trade is the only reason he kept it.

https://x.com/anishmoonka/status/2057854234536951872

Thanks for going down this rabbit hole ❤️

Follow @anishmoonka for daily stories across science, history, psychology, culture & AI.

—————

Sources:

SEC EDGAR, Broadcast.com Schedule 13D (Yahoo all-stock merger, 0.7722 exchange ratio)
<sec.gov/Archives/edgar…>

Liberty Through Wealth, full trade mechanics ($85 floor, $205 ceiling, 146,000 contracts, $237 peak, $13 trough)
<libertythroughwealth.com/2018/08/23/mar…>

MarketBeat, strike prices and over $1B cashed out
<marketbeat.com/learn/how-to-u…>

Celebrity Net Worth, 14.6M shares at $95, $1.4B, Yahoo’s stock as currency
<celebritynetworth.com/articles/billi…>

Benzinga, Broadcast.com shut down 2002 and Verizon’s $4.5B Yahoo purchase
<benzinga.com/general/educat…>

Part 2. Two college buddies built a website in 1995 just so they could listen to their old basketball team’s games from out of state. Three years later, it had the biggest opening day in stock market history, and it had never turned a single dollar of profit.

The two were Mark Cuban and his friend Todd Wagner. Both had gone to Indiana University, both were now stuck in Dallas, and neither could find a way to hear their college team play. So they built one. Cuban ran it out of the spare bedroom of his house with one computer server and a single internet line, living off the roughly $2 million he had made years earlier selling his first company. Plenty of people told him it was a stupid idea, that nobody would rig up a $4,000 computer to do the job of a $6 radio. As Cuban put it later, “People thought I was an idiot.”

They were just early. The site started streaming live audio in 1995, added video in 1997, and grew into the biggest place on the internet for live radio and online events. In 1998 they renamed it Broadcast .com and took it public.

On July 17, 1998, the stock was priced at $18 a share. By the time the first day of trading was over, it had closed near $63. The stock had more than tripled in a few hours, a 249% jump, and no company in the history of the American stock market had ever gained that much on its first day. On paper, Cuban’s slice of the company was suddenly worth around $300 million.

The business under that price had never made money. In all of 1997 it took in under $7 million in sales while losing more than $6 million, and its own official filing for the stock sale told investors in plain language to expect more losses for years. They bought it anyway, handing a money-losing project run out of a bedroom a price tag north of a billion dollars.

A spare-room hobby had turned Cuban into a paper multimillionaire, built almost entirely on hope about where the internet was headed. He had helped build one of the bubble’s brightest pieces with his own two hands, so he understood exactly how little was holding it up.

Read 6 tweets

Anish Moonka

@anishmoonka

May 21

https://x.com/anishmoonka/status/2057233730939314514

Toru Miyazaki gave 11 cats with advanced kidney disease an experimental injection. 15 others didn’t get it. A year later, 9 of the 11 treated cats were alive. Only 3 of the 15 untreated cats survived. He just filed for approval, and the drug fixes a defect only cats have.

Most cats die from one thing: their kidneys fail. By age 10, 4 in 10 cats already have chronic kidney disease, and by age 15, the rate doubles to 8 in 10. Once diagnosed, a cat has about 2 years left.

The reason kidney disease hits cats so hard is a broken protein in their blood. All mammals carry a protein that helps the kidneys clean out waste. In humans and dogs, the protein floats freely and goes to work when the kidneys are in trouble. In cats, it stays stuck to another protein and can’t get loose. So the waste piles up, and the kidneys eventually give out.

Miyazaki originally found the protein in 1999, back when he was at the University of Tokyo. He figured out the cat-specific glitch in 2015. The paper he published in the Veterinary Journal in February laid out the trial. The injection is a working version of the missing protein. His company, the Institute for AIM Medicine, filed the approval paperwork with Japan’s Ministry of Agriculture on April 24, 2026. If the review clears, the drug goes on sale in spring 2027.

The 30-year lifespan figure in the tweet is Miyazaki’s own projection of what cats could reach without kidney disease. The trial only ran a year, and the average cat today lives 15. Most die from the same disease this injection treats.

The research almost died in 2020. After running out of funding during COVID, Miyazaki went public. Cat owners across Japan responded by sending in 300 million yen, around 2 million dollars total. He resigned from the University of Tokyo and worked on the drug full time. The treatment in front of regulators today exists because cat lovers refused to let the research die.

https://x.com/anishmoonka/status/2057233730939314514

Thanks for going down this rabbit hole ❤️

Follow @anishmoonka for daily stories across science, history, psychology, culture & AI.

—————

Sources:

Clinical trial paper, Veterinary Journal, Tezuka et al. (Feb 2026): A clinical impact of apoptosis inhibitor of macrophage on feline chronic kidney disease sciencedirect.com/science/articl…

Japan Times (April 27, 2026): Japan startup seeks approval of cat kidney disease treatment japantimes.co.jp/news/2026/04/2…

AFP via France24 (April 27, 2026): Japan startup seeks approval of cat kidney disease treatment france24.com/en/live-news/2…

Institute for AIM Medicine official site iamaim.jp/en/

Institute for AIM Medicine topics page (clinical trial announcement) iamaim.jp/en/topics/

University of Tokyo feature on Miyazaki and the AIM protein u-tokyo.ac.jp/focus/en/featu…

Catster (Oct 2025): Promising New Feline Kidney Disease Treatment Enters Trials in Japan catster.com/weekly-mews/pr…

Carelogy (April 2026 update): AIM Kidney Drug for Cats - approval update, mechanism, expected cost carelogy-japan.com/en/columns/aim…

Labiotech (Aug 2025): How biotech is improving the life of your cat labiotech.eu/in-depth/cat-b…

Phys.org (April 2026): Japan startup seeks approval of cat kidney disease treatment phys.org/news/2026-04-j…

Mothership.SG (Feb 2026): Japanese doctor develops drug that may double lifespan of cats mothership.sg/2026/02/japane…

Yahoo News: Japanese scientist develops treatment that can help cats live up to 30 years yahoo.com/news/japanese-…

Cornell Feline Health Center: Chronic Kidney Disease in cats vet.cornell.edu/departments-ce…

Part 2. Behind the cat drug story is a bigger study. Miyazaki tracked 423 patients starting dialysis and 563 more with chronic kidney disease. The same protein from the cat trial predicted who would survive longer in humans too. Human kidney disease is next in the pipeline.

In humans, the protein usually works. It floats freely in the blood and attaches to damaged kidney cells, signaling the immune system to remove them. The problem comes when the protein doesn't release from its parent antibody fast enough. The dialysis study found that patients with slow release had higher death rates and more cardiovascular trouble over time. Speed of release became a way to predict risk.

More than 800,000 Americans currently live with end-stage kidney disease, about 517,000 of them on dialysis. Each dialysis patient costs Medicare $87,000 to $110,000 per year. The US dialysis market hit $30.9 billion in 2025 and is projected to nearly double by 2034. Despite recent drug approvals, no treatment has been able to halt or reverse advanced kidney disease.

The cat drug came first for a specific reason. Cats have the simplest version of the problem: replace one broken protein with a working version, and the kidney repair process turns back on. In humans, the protein already works. The challenge there is timing and how to push it to release faster when needed.

In 2024 Miyazaki's lab worked with London's Francis Crick Institute to map the exact shape of how the protein binds to its parent antibody. The paper went into Nature Communications. Knowing the binding shape is what makes designing human treatments possible.

AIM research extends beyond kidneys. Miyazaki's lab has published on its role in autoimmune arthritis, stroke recovery, liver cancer, kidney stones, and glaucoma.

Manufacturing is being set up in Taiwan. The cat drug ships first because it's the cleanest test. Everything else in Miyazaki's pipeline depends on it working.

Read 7 tweets

Anish Moonka

@anishmoonka

May 20

https://x.com/anishmoonka/status/2056847843743162448

Take too much Ozempic, and your brain stops wanting things: food, sex, even the urge to get out of bed. People end up in hospital beds for days, staring at the ceiling, feeling nothing. The medical name for that state is anhedonia, and it tells you how the drug actually works.

Ozempic, Wegovy, and Mounjaro all belong to the same drug family, called GLP-1s. They kill hunger. They also quiet almost every other craving your brain produces.

Inside your brain there is a small region that makes a chemical called dopamine. Dopamine is your brain’s “this is worth wanting” chemical, the reason you reach for one more bite of pasta, refresh your inbox one more time, or pick up your phone every few minutes. GLP-1 drugs reach that region and turn the dopamine down. The right dose dampens the loudest craving first: food. Take too much, and the volume drops on everything else, sex, exercise, work, even the urge to get out of bed in the morning.

Anhedonia is the medical name for not feeling pleasure from anything at all. It looks identical to deep depression. The good news is that anhedonia from GLP-1s has an off switch: once the drug clears your system, the wanting comes back.

The FDA has logged over 1,150 reports of bad reactions tied to compounded GLP-1s through July 2025. These are custom-mixed versions made by smaller pharmacies. In many of those cases, patients accidentally took five to twenty times their prescribed dose. The cause is usually confusion between milliliters and units when measuring out a dose with an insulin syringe, since compounded versions come in plain vials instead of the pre-filled pens that brand-name Ozempic uses.

About 15 million Americans currently use a GLP-1, roughly one in eight adults. Around 75% of them eventually quit. Cost and side effects are the top reasons. A growing number describe a third reason that patients call “the lights dimming,” a flat, gray feeling across the whole day that doctors now recognize as anhedonia caused by the drug itself.

This same mechanism has caught pharma’s attention. Eli Lilly is now running two large clinical trials with a combined 2,200 patients to see if a GLP-1 drug can treat alcohol addiction. The bet is that the same brain switch that turns off cravings for food can also turn off cravings for alcohol, cocaine, nicotine, and gambling. A 2026 psychiatry review put it bluntly: doctors should be treating these as psychiatric drugs, because that is what they have turned out to be.

The drug works by quieting your brain’s signal that something is worth wanting. A normal dose turns the volume down on food cravings. Push the dose too high, and everything else goes quiet too.

https://x.com/anishmoonka/status/2056847843743162448

Thanks for going down this rabbit hole ❤️

Follow @anishmoonka for daily stories across science, history, psychology, culture & AI.

—————

Sources:

FDA alert on dosing errors with compounded GLP-1 drugs and 1,150+ adverse event reports through July 2025
fda.gov/drugs/postmark…

UIC Drug Information Group review of compounded semaglutide and tirzepatide overdoses showing patients took 5 to 20 times the prescribed dose
dig.pharmacy.uic.edu/faqs/2025-2/ja…

National Consumers League update tracking 1,150 FDA adverse event reports for compounded GLP-1s as of July 31, 2025
nclnet.org/the-real-cost-…

Science Advances paper showing GLP-1 receptor activation reduces dopamine release in the brain’s reward circuit
science.org/doi/10.1126/sc…

PMC review on GLP-1 mechanisms in craving and addiction through the mesolimbic dopamine pathway
pmc.ncbi.nlm.nih.gov/articles/PMC12…

Osmind clinician analysis of GLP-1 drugs as psychiatric medication and Eli Lilly’s brenipatide Phase 3 trials for alcohol use disorder
osmind.org/articles/glp-1…

KFF national poll showing about 1 in 8 U.S. adults currently use a GLP-1 drug, with cost and side effects as the top discontinuation reasons
kff.org/health-costs/k…

GBC Health overview of 15 million GLP-1 users in the U.S. and the 75% discontinuation rate
gbchealth.org/glp-1-drugs/

Today.com feature on Ozempic Personality, anhedonia, and the patient description of the lights dimming
today.com/health/diet-fi…

Supermind Hacker analysis of iatrogenic anhedonia from GLP-1 drugs and the dopamine suppression mechanism
supermindhacker.substack.com/p/the-ozempic-…

Part 2. Most people know Ozempic as a weight loss drug. The trial data is starting to look like weight loss is the side effect. In the largest study ever done on the drug, it cut heart attacks and strokes by 20%. And the protection kicked in before any weight came off.

That study was called SELECT. It tested semaglutide, the molecule in Ozempic and Wegovy, in 17,604 people with existing heart disease for about three and a half years. Alongside the 20% drop in major cardiac events, deaths from any cause fell 19% and heart failure events fell 18%. The FDA approved Wegovy for cardiovascular protection off the back of this single trial.

Then came FLOW, a separate kidney disease trial in 3,533 patients. It got stopped early because the results were too strong. Semaglutide cut the risk of kidney failure, kidney-related death, and major heart events by 24%, and deaths from any cause by 20%.

The same molecule keeps showing up in other organs. In a sleep apnea trial of nearly 500 obese patients, the related drug Zepbound cut breathing disruptions during sleep by 25 to 29 per hour. About half of the people on the highest dose were effectively cured of sleep apnea. The FDA approved that use in December 2024.

In a liver disease trial called ESSENCE, 63% of patients on semaglutide cleared the fatty inflammation that drives the worst form of liver disease, compared to 34% on placebo. The FDA approved Wegovy for that use last August.

GLP-1 drugs (the class that includes Ozempic, Wegovy, Mounjaro, and Zepbound) do a lot of things in the body at the same time. They lower blood pressure, drop inflammation markers in the blood, improve cholesterol numbers, and act directly on receptors built into the heart and blood vessels. That is why the drug seems to calm the underlying biology first, and the weight loss follows later.

Some cardiologists now compare this drug class to statins, the cholesterol drugs that became standard preventive medicine in the 1990s. Yale’s Harlan Krumholz has told reporters the cardiovascular benefit is “largely independent of the amount of weight loss achieved.” Global GLP-1 sales hit an annualized rate of around $25 billion by late 2023, already close to double what statins ever made at their peak.

Doctors running these trials are starting to describe Ozempic as a heart and metabolic protection drug that happens to cause weight loss as a side effect. If these numbers hold up in everyday practice, this might end up being the most important class of drugs since statins.

Read 7 tweets

Anish Moonka

@anishmoonka

May 18

https://x.com/anishmoonka/status/2056039903860064677

A baby this age usually switches toys every 2-3 minutes. This duck stair toy holds their attention 10-15 minutes straight. Watch the baby's face. It's the focus a scientist gets when an experiment is finally working.

The experiment goes like this: "is the duck going to fall down again?" After the first cycle, the baby's brain has learned the rule, and every duck after that becomes a fresh test of it. The duck climbs, reaches the top, falls down the slide, and the prediction gets confirmed. Every confirmed prediction triggers a tiny pulse of dopamine, the same brain chemical you get when you finally remember where you put your keys. To a baby, watching the duck do the expected thing feels the way solving a small puzzle feels to you.

Researchers at the University of Rochester gave this its name back in 2012. They call it the Goldilocks Effect. Celeste Kidd's lab tracked 72 seven-month-old babies as they watched videos that ranged from very predictable to completely random. The babies looked away when the videos got too boring. They also gave up when things turned too random. They stayed glued only when the pattern landed somewhere in the middle, predictable enough to follow, surprising enough to feel interesting.

The duck staircase lives in exactly that zone. The rule is simple. But each loop has just enough variation, the order the ducks come in, the bounce of the slide, the timing of each fall, to keep the brain busy checking its own predictions.

Bright yellow on a pale frame. At four months old, a baby's vision is about a third as sharp as yours, so soft pastel colors blur into mush, but high-contrast colors pop out clearly. The whole toy is also constantly moving, and babies prefer moving things to still things from their first month of life. A baby's brain forms about a million new connections every second during their first year, so anything moving is a free chance to learn.

Compare the duck toy to a fast-cut video on a phone screen. The brain can't pull a pattern from thousands of unpredictable pixels per second, so attention drops. Now compare it to a plain wooden block. Nothing is changing, so there's nothing to predict, and attention drops the other way. The duck on the stairs is the rare toy that lands right between too-much and too-little. It's why this baby can stare at it for fifteen minutes while a $300 educational toy gets two. The duck toy costs about fifteen bucks.

https://x.com/anishmoonka/status/2056039903860064677

Thanks for going down this rabbit hole ❤️

Follow @anishmoonka for daily stories across science, history, psychology, culture & AI.

—————

Sources:

Kidd, Piantadosi and Aslin (2012) - The Goldilocks Effect: Human Infants Allocate Attention to Visual Sequences That Are Neither Too Simple Nor Too Complex, PLoS ONE
journals.plos.org/plosone/articl…

Kidd, Piantadosi and Aslin (2014) - The Goldilocks Effect in Infant Auditory Attention, NIH PubMed Central
pmc.ncbi.nlm.nih.gov/articles/PMC48…

Infant Visual Development (Wikipedia) - motion preference from one month, acuity timeline
en.wikipedia.org/wiki/Infant_vi…

American Academy of Pediatrics on cognitive development 8-12 months, attention span norms
healthychildren.org/English/ages-s…

Synaptic pruning explainer (Healthline) - visual cortex synapse production peaks at 8 months, Huttenlocher 1979 review
healthline.com/health/synapti…

Part 2. A 2018 University of Toledo study put 36 toddlers in two rooms. One room had 4 toys. The other had 16. The kids with fewer toys played twice as long with each one and got twice as creative. The duck toy in this video is doing the same thing in faster motion.

While the baby stares at the duck climbing the stairs, their brain is running its first physics class. Object permanence is showing up in real time, since the duck still exists when it disappears at the top of the slide. Cause and effect arrives through the wind-up mechanism reliably producing motion. And the basic law of gravity is right there too, in every duck that falls down and never up. Jean Piaget identified these as the foundation of all future learning. Modern research moved the timeline a few months earlier than Piaget thought, but the principle holds: this is when the basic operating system of the human mind gets installed.

The global educational toy market is worth $71 billion and projected to hit $148 billion by 2034. Most of what fills that market does the learning for the baby. The toy speaks the words and plays the songs. It lights up on cue. The baby's brain was built to figure out patterns on its own, but it gets handed pre-figured patterns instead. There is nothing left to figure out.

The duck toy works in the opposite direction. The baby has to construct meaning from raw input, which is exactly the work the brain evolved to do. Researchers have a name for this kind of brain workout: active learning. The Toledo team found that giving toddlers fewer toys helps them focus and play more creatively, and the effect showed up in just thirty minutes of observation.

For parents watching this video: rotate toys instead of accumulating them, since the Toledo study suggests four at a time is plenty. And look for toys where the baby has to do the work. A flashing electronic toy gives them the answer, while the duck toy makes them earn every insight. Same fifteen minutes of play, completely different brains at the end of it.

Read 4 tweets

Share this page!

Enter URL or ID to Unroll

Anish Moonka

Try unrolling a thread yourself!

More from @anishmoonka

Anish Moonka

Anish Moonka

Anish Moonka

Anish Moonka

Anish Moonka

Anish Moonka

Did Thread Reader help you today?

Don't want to be a Premium member but still want to support us?

Send Email!